{"id":"baycuten-n","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation or sensitization"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Skin atrophy with prolonged use"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The formulation typically combines a potent topical corticosteroid (such as betamethasone) with an antimicrobial component (such as neomycin or gentamicin) to address inflammatory skin disorders complicated by or at risk of secondary bacterial infection. The corticosteroid suppresses local immune response and inflammation, while the antimicrobial component provides broad-spectrum bacterial coverage.","oneSentence":"Baycuten N is a topical combination product containing a corticosteroid and an antimicrobial agent that reduces inflammation and prevents bacterial infection in skin conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:36.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions with secondary bacterial infection or infection risk (e.g., eczema, dermatitis, impetigo)"}]},"trialDetails":[{"nctId":"NCT05285813","phase":"PHASE2","title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-05-06","conditions":"AML, MDS","enrollment":42},{"nctId":"NCT02514382","phase":"PHASE1","title":"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2015-08-21","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":14},{"nctId":"NCT01239797","phase":"PHASE3","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-06-20","conditions":"Lymphoma, Multiple Myeloma","enrollment":646},{"nctId":"NCT02582177","phase":"PHASE3","title":"Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2019-06-11","conditions":"Tinea","enrollment":125},{"nctId":"NCT00671034","phase":"PHASE3","title":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-07-21","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia","enrollment":166},{"nctId":"NCT00258245","phase":"PHASE1","title":"Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2005-05","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["clotrimazole and dexamethasone acetate"],"phase":"phase_3","status":"active","brandName":"Baycuten N®","genericName":"Baycuten N®","companyName":"Ache Laboratorios Farmaceuticos S.A.","companyId":"ache-laboratorios-farmaceuticos-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baycuten N is a combination treatment that includes arsenic trioxide, ascorbic acid, and bortezomib. It has been studied in clinical trials for various blood cancers, including multiple myeloma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and plasma cell neoplasms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}